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For many years, there was no effective treatment for
severe chronic neutropenia. Patients were simply pre-
scribed antibiotics, when they developed fever and infec-
tions. Recombinant human granulocyte colony-stimulating
factor (G-CSF) dramatically changed this situation, when it
became available for clinical studies in 1986. Soon there-
after evidence from small trials suggested that G-CSF was
useful for treatment of cyclic, congenital, and idiopathic
neutropenia. A randomized controlled trial then established
that daily subcutaneous G-CSF, given in doses to achieve
a blood neutrophil count of approximately 2.0 3 109/L,
could reduce the occurrence of fever, mouth ulcers, infec-
tions, and antibiotic use in these patients [1]. Although this
trial proved the efﬁcacy of G-CSF therapy as a preventive
therapy for severe chronic neutropenia, it did not provide
precise guidelines for the best ways to care for these
patients.
In this issue of the Journal, Fioredda et al. [2] report con-
sensus guidelines for therapy and follow-up of children with
congenital and acquired neutropenia. The report is based
on a careful review of the literature and grading the evi-
dence in 59 reports by an expert panel of Italian hematolo-
gists. The evidence in these reports was scored by the
experts on a scale of 1–9. Statements receiving a mean
score that was greater than 7 were regarded as appropri-
ate/necessary clinical practices. Statements about treat-
ment are referenced, and the level of evidence and the
level and strength of the consensus are also provided. The
panel is to be commended for the careful way they con-
ducted and presented these guidelines.
Since 1994, another group, the Advisory Board for the
Severe Chronic Neutropenia International Registry (SCNIR
or Registry), has also engaged in developing treatment rec-
ommendations and guidelines for these patients [3–7]. The
Registry’s efforts are based on data from patients enrolled
in the original Phase 2 and Phase 3 trials and prospectively
collected data from a much larger group of patients en-
rolled subsequently in the Registry. The board meets annu-
ally and communicates regularly about individual patients.
Annually, the board reviews new and cumulative clinical
observations, by diagnostic category, by speciﬁc/genetic di-
agnosis, and by geographic origin. It also discusses
adverse events, reviews, and revises treatment recommen-
dations, and periodically published reports from this longitu-
dinal, observational study.
The Italian report includes the reports and observations
of the SCNIR and largely conﬁrms its recommendations.
This is important, because the SCNIR was originally spon-
sored by Amgen, a US manufacturer of G-CSF, and the
physicians directing the SCNIR have a potential conﬂict of
interest in making recommendations regarding this agent.
By contrast, the expert panel for this report does not have
this conﬂict, but it reached the same conclusions regarding
G-CSF therapy based on its review of evidence.
This report provides recommendations about several
controversial issues that differ somewhat from the recom-
mendations and statements for the SCNIR. For example,
for patients with glycogen storage disease, the report does
not mention the problem of severe splenomegaly, when
these patients receive G-CSF therapy; the SCNIR advises
physicians of this concern and advises using the lowest
possible G-CSF dose to minimize this problem. The report
advises that Shwachman–Diamond syndrome may be at
greater risk of leukemic transformation and therefore
advises ‘‘on-demand’’ G-CSF. The recommendation is not
referenced, and the relationship of G-CSF treatment and
the risk of leukemic transformation are not known. The
SCNIR recommends continuous G-CSF for patients with
severe neutropenia and recurrent fever and infections,
regardless of the type of neutropenia. The report is also
limited to children, but approximately half of the patients
now in the SCNIR are now of adult age. The SCNIR makes
recommendations for the continuum of ages, including both
children and adults. Table 2 provides expert recommenda-
tions about the frequency of biochemical parameters and
abdominal ultrasound; the SCNIR has not evaluated or
made recommendations about these tests. Overall, how-
ever, these are minor points, and these guidelines are very
useful for improving the care of patients with these rare
hematological diseases.
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